Success Metrics

Clinical Success Rate
90.9%

Based on 10 completed trials

Completion Rate
91%(10/11)
Active Trials
0(0%)
Results Posted
50%(5 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
3
27%
Ph phase_3
4
36%
Ph phase_1
4
36%

Phase Distribution

4

Early Stage

3

Mid Stage

4

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
4(36.4%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
4(36.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.9%

10 of 11 finished

Non-Completion Rate

9.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(10)
Terminated(1)

Detailed Status

Completed10
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
90.9%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (36.4%)
Phase 23 (27.3%)
Phase 34 (36.4%)

Trials by Status

terminated19%
completed1091%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_3

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

NCT05520177
completedphase_1

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151
terminatedphase_3

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

NCT02032173
completedphase_2

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

NCT03499223
completedphase_3

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01922102
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT05520177Phase 3

A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

Completed
NCT02140151Phase 1

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

Completed
NCT02032173Phase 3

Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase

Terminated
NCT03499223Phase 2

A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)

Completed
NCT01922102Phase 3

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia

Completed
NCT02302989Phase 1

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

Completed
NCT01948830Phase 3

Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD

Completed
NCT01037348Phase 2

Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen

Completed
NCT01926977Phase 1

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

Completed
NCT01471691Phase 1

Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab

Completed
NCT01112085Phase 2

MIcrodoses of raNIbizumab in Diabetic MAcular Edema (MINIMA-2)

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11